Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => 7期肝癌的诊断和治疗 => 肝纤维化及肝硬化 =>
Influence of daclatasvir hydrochloride combined with asunaprevir on renal function in patients with compensated hepatitis C cirrhosis
文章发布日期:2018年06月07日  来源:  作者:梁志军,王素娜  点击次数:670次  下载次数:112次
Adjust font size:Small regular big

【Abstract】:Objective To investigate the influence of daclatasvir hydrochloride combined with asunaprevir on renal function in patients with compensated hepatitis C cirrhosis. Methods A total of 44 previously untreated patients with compensated hepatitis C cirrhosis caused by hepatitis C virus genotype 1b infection who visited Department of Infectious Diseases in Tangdu Hospital, Fourth Military Medical University, from May 2017 to September 2017 were enrolled. All patients were given oral daclatasvir hydrochloride (60 mg, once a day) combined with asunaprevir (100 mg, twice a day) as the antiviral therapy, and the course of treatment was 24 weeks. The changes in HCV RNA clearance rate, alanine aminotransferase (ALT) normalization rate, blood urea nitrogen, creatinine, and estimated glomerular filtration rate (eGFR) were measured from baseline to weeks 4 and 24 of treatment were observed, and eGFR was calculated using the Modification of Diet In Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. The chi-squared test was used for comparison of normally distributed continuous data between groups, and the SNK-q test was used for further comparison between two groups. Results At week 24 of treatment, the HCV RNA clearance rate was 100% (44/44) and the ALT normalization was 97.50% (39/40). There was a significant increase in blood urea nitrogen from baseline (4.43±1.09 mmol/L) to week 24 of treatment (4.91±1.41 mmol/L) (q=2.322, P=0.025), while there was no significant change in creatinine from baseline to week 4 or 24 of treatment (both P>0.05). There was no significant change in eGFR calculated using either MDRD or CKD-EPI equation from baseline to week 4 or 24 of treatment (both P>0.05). As for the 14 patients with a baseline eGFR of <90 ml/min/1.73m2 calculated using the MDRD equation, they had a significant increase in eGFR from baseline (82.81±7.16 ml/min/1.73 m2) to week 24 of treatment (89.65±15.85 ml/min/1.73 m2) (q=2.303, P=0.038). Conclusion Daclatasvir hydrochloride combined with asunaprevir has no significant influence on renal function in patients with compensated hepatitis C cirrhosis, and there is a need for more studies with a large sample size.
【Key words】:hepatitis C; liver cirrhosis; kidney function tests; antiviral agents

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号